Molecular genetics of brain tumors-an overview

Handbook of Brain Tumor Chemotherapy

Volumn , Issue , 2006, Pages 115-122

  Demuth, Tim ^a   Berens, Michael E ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959932756     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088410-0/50046-9     Document Type: Chapter

References (72)

1. Kleihues P.C.W. Pathology & Genetics of Tumours of the Nervous System 2000, IARC Press, New York. 2nd ed.
2. Kleihues P., Louis D.N., Scheithauer B.W., et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002, 61:215-225. (discussion 226-219).
3. Martinez R., Schackert H.K., Plaschke J., Baretton G., Appelt H., Schackert G. Molecular mechanisms associated with chromosomal and microsatellite instability in sporadic glioblastoma multiforme. Oncology 2004, 66:395-403.
4. Martinez R., Schackert H.K., Appelt H., Plaschke J., Baretton G., Schackert G. Low-level microsatellite instability phenotype in sporadic glioblastoma multiforme. J Cancer Res Clin Oncol 2004, 131:87-93.
5. Biernat W., Huang H., Yokoo H., Kleihues P., Ohgaki H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 2004, 14:131-136.
6. Pardo F.S., Hsu D.W., Zeheb R., Efird J.T., OkunieffP.G., Malkin D.M. Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage. Br J Cancer 2004, 91:1678-1686.
7. Hayashi Y., Yamashita J., Watanabe T. Molecular genetic analysis of deep-seated glioblastomas. Cancer Genet Cytogenet 2004, 153:64-68.
8. Stander M., Peraud A., Leroch B., Kreth F.W. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis. Cancer 2004, 101:1028-1035.
9. Mayo L.D., Dixon J.E., Durden D.L., Tonks N.K., Donner D.B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 2002, 277:5484-5489.
10. Mizoguchi M., Nutt C.L., Mohapatra G., Louis D.N. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol 2004, 14:372-377.
11. Knobbe C.B., Reifenberger J., Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol (Berl) 2004, 108:467-470.
12. Jeuken J.W., von Deimling A., Wesseling P. Molecular pathogenesis of oligodendroglial tumors. J Neurooncol 2004, 70:161-181.
13. Barbashina V., Salazar P., Holland E.C., Rosenblum M.K., Ladanyi M. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005, 11:1119-1128.
14. Daido S., Takao S., Tamiya T., et al. Loss of heterozygosity on chromosome 10q associated with malignancy and prognosis in astrocytic tumors, and discovery of novel loss regions. Oncol Rep 2004, 12:789-795.
15. Ohgaki H., Dessen P., Jourde B., et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004, 64:6892-6899.
16. Batchelor T.T., Betensky R.A., Esposito J.M., et al. Agedependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004, 10:228-233.
17. Shinojima N., Tada K., Shiraishi S., et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003, 63:6962-6970.
18. Burton E.C., Lamborn K.R., Feuerstein B.G., et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res 2002, 62:6205-6210.
19. Wang Y., Zhu S., Cloughesy T.F., Liau L.M., Mischel P.S. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 2004, 23:1283-1290.
20. Watanabe T., Katayama Y., Komine C., et al. O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 2005, 113:581-587.
21. Leuraud P., Taillandier L., Medioni J., et al. Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations. Cancer Res 2004, 64:4648-4653.
22. Mollemann M., Wolter M., Felsberg J., Collins V.P., Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005, 113:379-385.
23. Fuller C.E., Perry A. Pathology of low- and intermediate-grade gliomas. Semin Radiat Oncol 2001, 11:95-102.
24. Nutt C.L., Mani D.R., Betensky R.A., et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003, 63:1602-1607.
25. Freije W.A., Castro-Vargas F.E., Fang Z., et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004, 64:6503-6510.
26. Sallinen S.L., Sallinen P.K., Haapasalo H.K., et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 2000, 60:6617-6622.
27. Ljubimova J.Y., Khazenzon N.M., Chen Z., et al. Gene expression abnormalities in human glial tumors identified by gene array. Int J Oncol 2001, 18:287-295.
28. Rickman D.S., Bobek M.P., Misek D.E., et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001, 61:6885-6891.
29. Demuth T., Berens M.E. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 2004, 70:217-228.
30. Mariani L., Beaudry C., McDonough W.S., et al. Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis. J Neurooncol 2001, 53:161-176.
31. Tran N.L., McDonough W.S., Savitch B.A., Sawyer T.F., Winkles J.A., Berens M.E. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005, 280:3483-3492.
32. Nakada M., Niska J.A., Miyamori H., et al. The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells. Cancer Res 2004, 64:3179-3185.
33. Asano K., Duntsch C.D., Zhou Q., et al. Correlation of N-cadherin expression in high grade gliomas with tissue invasion. J Neurooncol 2004, 70:3-15.
34. Soroceanu L., Manning T.J., Sontheimer H. Reduced expression of connexin-43 and functional gap junction coupling in human gliomas. Glia 2001, 33:107-117.
35. Ding Q., Stewart J., Prince C.W., et al. Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res 2002, 62:5336-5343.
36. Forget M.A., Desrosiers R.R., Del M., et al. The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. Clin Exp Metastasis 2002, 19:9-15.
37. Ridley A.J., Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992, 70:389-399.
38. Joy A.M., Beaudry C.E., Tran N.L., et al. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 2003, 116:4409-4417.
39. Hoelzinger D.B., Mariani L., Weis J., et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005, 7:7-16.
40. Zagzag D., Salnikow K., Chiriboga L., et al. Down-regulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest 2005, 85:328-341.
41. Forsyth P.A., Wong H., Laing T.D., et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999, 79:1828-1835.
42. Nakada M., Nakamura H., Ikeda E., et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 1999, 154:417-428.
43. Tonn J.C., Kerkau S., Hanke A., et al. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer 1999, 80:764-772.
44. Tonn J.C., Goldbrunner R. Mechanisms of glioma cell invasion. Acta Neurochir Suppl 2003, 88:163-167.
45. Whittaker M., Floyd C.D., Brown P., Gearing A.J. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999, 99:2735-2776.
46. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
47. Groves M.D., Puduvalli V.K., Hess K.R., et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002, 20:1383-1388.
48. Leins A., Riva P., Lindstedt R., DavidoffM.S., Mehraein P., Weis S. Expression of Tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 2003, 98:2430-2439.
49. Zagzag D., Friedlander D.R., Miller D.C., et al. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 1995, 55:907-914.
50. Zagzag D., Friedlander D.R., Dosik J., et al. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 1996, 56:182-189.
51. Kostianovsky M., Greco M.A., Cangiarella J., Zagzag D. Tenacin-C expression in ultrastructurally defined angiogenic and vasculogenic lesions. Ultrastruct Pathol 1997, 21:537-544.
52. Zagzag D., ShiffB., Jallo G.I., et al. Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. Cancer Res 2002, 62:2660-2668.
53. Wenk M.B., Midwood K.S., Schwarzbauer J.E. Tenascin-C suppresses Rho activation. J Cell Biol 2000, 150:913-920.
54. Bigner D.D., Brown M., Coleman R.E., et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2-a preliminary report. J Neurooncol 1995, 24:109-122.
55. Kurpad S.N., Zhao X.G., Wikstrand C.J., Batra S.K., McLendon R.E., Bigner D.D. Tumor antigens in astrocytic gliomas. Glia 1995, 15:244-256.
56. Reardon D.A., Akabani G., Coleman R.E., et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002, 20:1389-1397.
57. Goetz C., Riva P., Poepperl G., et al. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J Neurooncol 2003, 62:321-328.
58. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
59. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
60. Iwadate Y., Sakaida T., Hiwasa T., et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004, 64:2496-2501.
61. Zhang R., Tremblay T.L., McDermid A., Thibault P., Stanimirovic D. Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. Glia 2003, 42:194-208.
62. Grubb R.L., Calvert V.S., Wulkuhle J.D., et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 2003, 3:2142-2146.
63. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res 2001, 61:3225-3229.
64. Esteller M., Cordon-Cardo C., Corn P.G., et al. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 2001, 61:2816-2821.
65. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4:143-153.
66. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
67. Stone A.R., Bobo W., Brat D.J., Devi N.S., Van Meir E.G., Vertino P.M. Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol 2004, 165:1151-1161.
68. Yu J., Zhang H., Gu J., et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 2004, 4:65.
69. Knobbe C.B., Reifenberger J., Blaschke B., Reifenberger G. Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. J Natl Cancer Inst 2004, 96:483-486.
70. Waha A., Guntner S., Huang T.H., et al. Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia 2005, 7:193-199.
71. Leone G., Voso M.T., Teofili L., Lubbert M. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol 2003, 109:89-102.
72. Pan K.H., Lih C.J., Cohen S.N. Analysis of DNA microarrays using algorithms that employ rule-based expert knowledge. Proc Natl Acad Sci USA 2002, 99:2118-2123.